Vivek Das: How Obesity, Type 2 Diabetes, and Dyslipidaemia Interact Across Multiple Cardiovascular Conditions
Vivek Das, Lead Data Scientist at Novo Nordisk, shared a post on LinkedIn about a recent article by Paul C Evans, published in European Heart Journal, adding:
“A noticeable shift in cardiometabolic research is the move from isolated risk factors toward a more integrated, mechanism – driven view of disease.
Recent work highlights how obesity, type 2 diabetes, and dyslipidaemia interact across multiple cardiovascular conditions, rather than acting independently.
As biology becomes more interconnected, it reshapes how patients are stratified, how endpoints are defined, and how evidence is generated across the lifecycle.
For complex chronic diseases, the challenge is no longer identifying signals, but translating interconnected biology into coherent evidence that can inform decisions at scale.”
Title: Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities: A scientific statement of the ESC Council on Basic Cardiovascular Science, the ESC Working Group on Atherosclerosis and Vascular Biology, the ESC Working Group on Cellular Biology of the Heart, the ESC Working Group on Myocardial Function, and the ESC Working Group on Cardiac Cellular Electrophysiology
Authors: Paul C Evans, Gemma Vilahur, Petra Kleinbongard, Elena Osto, Carol Ann Remme, Rosalinda Madonna, Dunja Aksentijevic, Harald Sourij, Sean M Davidson, Donato Santovito, Jürgen Gindlhuber, Christian Weber, Wolfgang A Linke, Esther Lutgens, Luc Bertrand, Dana Dawson, Magnus Bäck, G Danilo Norata, Johann Wojta, Cinzia Perrino
Read the Full Article on European Heart Journal
Stay updated on all scientific advances with Hemostasis Today.
-
May 23, 2026, 16:55Rahul Bhargava: Ensure Equal Recognition of Clinical Haematologists in Blood Cancer Clinical Trials
-
May 23, 2026, 16:44Brian O Mahony: World Haemophilia Day Receives Global WHO Recognition
-
May 23, 2026, 16:44Yusuf Hameed: Gene Therapy Could Reduce Lifetime Treatment Burden in Hemophilia A
-
May 23, 2026, 16:43Chokri Ben Lamine: Pacritinib Is a Key JAK Inhibitor for Cytopenic Myelofibrosis
-
May 23, 2026, 16:42Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
-
May 23, 2026, 16:42Shimels Tessema: Celebrating the WHA Resolution on Hemophilia and Other Bleeding Disorders
-
May 23, 2026, 16:38José Octavio Alva Bucio: Securing the Future of Plasma and Blood-Derived Medicines
-
May 23, 2026, 16:33Why Are We Dismantling What Powers Humanity and the Global Economy? – ASH
-
May 23, 2026, 16:24Marc Wittwer: A Practical Viscoelastic-Guided Algorithm for Trauma-Induced Coagulopathy in Clinical Workflow